GASTRIC NEUROENDOCRINE CARCINOMA
Clinical trials for GASTRIC NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo takes on 50+ rare cancers in major trial
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) in over 800 people with more than 50 types of rare cancers. The goal is to see if this treatment can shrink tumors by helping the immune system attack cancer cells. The study is for patie…
Matched conditions: GASTRIC NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Newer chemo combo fails to outperform standard in rare gut cancer trial
Disease control OngoingThis study tested whether a combination of temozolomide and capecitabine works better than the standard cisplatin and etoposide for people with advanced neuroendocrine cancer of the gut or pancreas that cannot be removed by surgery. The trial enrolled 67 participants and was stop…
Matched conditions: GASTRIC NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 11, 2026 20:50 UTC